Swog Cancer Research Network

This study tests whether adding either tazemetostat or zanubrutinib to a standard two-drug therapy (tafasitamab and lenalidomide) can better control relapsed or refractory large B-cell lymphoma in people who are not eligible for a stem cell transplant. About 227 participants will…

This study is for people newly diagnosed with AL amyloidosis, a rare disease where abnormal proteins damage organs. It compares two treatment approaches: chemotherapy followed by a stem cell transplant versus chemotherapy alone. The goal is to see which strategy better controls t…

This study tests whether adding a second chemotherapy drug (carboplatin) to the standard chemo (cabazitaxel) helps men with advanced prostate cancer that has spread and stopped responding to hormone therapy. About 528 participants will be randomly assigned to receive either cabaz…

This study is for people with extensive-stage small cell lung cancer (ES-SCLC). It tests whether using specific features of a person's tumor (biomarkers) can help doctors choose the best maintenance treatment to keep the cancer under control after initial therapy. Participants wi…

This study tests whether giving two chemotherapy drugs (capecitabine and temozolomide) after surgery can stop or delay high-risk pancreatic neuroendocrine tumors from coming back. About 141 participants will be randomly assigned to receive the drugs or just be watched. The goal i…

This study is for men with prostate cancer that has spread to other parts of the body. It compares standard drug therapy alone versus standard therapy plus either surgery to remove the prostate or radiation to the prostate. The goal is to see if adding local treatment helps patie…

This study tests whether adding ramucirumab to tepotinib works better than tepotinib alone for people with a certain type of advanced lung cancer (MET exon 14 skipping). Tepotinib blocks a faulty protein that makes cancer grow, while ramucirumab may cut off the tumor's blood supp…

This study is for people with kidney cancer that has spread to other parts of the body. It compares standard immunotherapy drugs (like nivolumab and axitinib) alone versus the same drugs plus surgery to remove the affected kidney. The goal is to see if adding surgery helps patien…

This study tests whether adding a targeted drug called panitumumab to standard chemotherapy can help people with a specific type of advanced pancreatic cancer (KRAS wild-type) live longer. About 94 adults whose cancer has spread or can't be removed will receive either chemo alone…

This study is for people with certain types of lymphoma that came back or didn't respond to treatment. After receiving CAR T-cell therapy, participants will get one or two additional drugs (mosunetuzumab and/or polatuzumab vedotin) to see if they help keep the cancer from returni…

This study compares a shorter chemotherapy-immunotherapy combination without anthracyclines to the usual treatment for early-stage triple-negative breast cancer. About 2,400 participants will receive either the experimental shorter regimen or standard care. The goal is to see if …

This study compares two treatment options for people with advanced small bowel cancer that has spread or is no longer responding to therapy. One group receives a combination of ramucirumab (a targeted antibody) and paclitaxel (chemotherapy), while the other receives FOLFIRI (a st…

This study tests whether giving the chemotherapy drug carboplatin before surgery can shrink tumors in men with high-risk prostate cancer who have inherited BRCA1 or BRCA2 gene mutations. About 44 participants will receive carboplatin before their prostate surgery. The goal is to …

This study tests a drug called amivantamab, given as a shot under the skin, for people with advanced non-small cell lung cancer that has extra copies of the MET gene. About 88 participants will receive the drug to see if it can shrink tumors or slow the cancer's growth. The goal …

This study tests whether a combination of targeted drugs (encorafenib and binimetinib) plus an immunotherapy (nivolumab) works better than two immunotherapies (ipilimumab and nivolumab) for people with BRAF-V600 mutant melanoma that has spread to the brain. About 112 adults with …

This study tests whether adding the immunotherapy drug cemiplimab to the standard two-drug combination (docetaxel and ramucirumab) can help people with advanced or recurrent non-small cell lung cancer live longer. Participants have already tried platinum-based chemotherapy and im…

This study tests whether combining three targeted drugs (capmatinib, osimertinib, and ramucirumab) works better than two drugs alone for people with advanced non-small cell lung cancer that has specific EGFR and MET gene changes. The drugs block signals that help cancer grow and …

This study tests three ways to prevent nerve damage (numbness, tingling, pain) caused by taxane chemotherapy. About 777 cancer patients will wear special wraps that cool and/or compress their arms and legs during treatment. The goal is to see which method best stops peripheral ne…

This study tests if giving the drug lanreotide before pancreatic surgery can prevent a common complication called a pancreatic fistula, where digestive fluids leak from the pancreas. About 274 people with pancreatic cancer or pre-cancerous lesions will be randomly assigned to rec…

This large study screens up to 10,000 people with previously treated non-small cell lung cancer to find specific genetic markers in their tumors. Based on those markers, participants may be assigned to a sub-study testing a new targeted therapy or immunotherapy. The goal is to le…

This study tests a web-based program called Current Together after Cancer (CTAC) to help people who had surgery for stage II or III colorectal cancer get the right follow-up tests. Many survivors miss these important checkups, which can catch cancer if it comes back early. The pr…

This study looks at people with HER2+ breast cancer that has spread. All are taking trastuzumab, a targeted therapy. The main goal is to track how often heart problems occur. A smaller part of the study tests if the heart drug carvedilol can prevent these side effects.

This study follows over 2,000 cancer patients receiving immunotherapy to see why some develop mild or serious side effects. Researchers will look at factors like age, gender, and other health conditions. The goal is to help doctors choose safer treatments in the future.

This study is testing whether using simple blood tests (tumor markers) to decide when to do scans is as good as the usual approach of regular scans for people with advanced hormone receptor-positive breast cancer. About 739 participants will be randomly assigned to either blood t…